These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 33389788)

  • 1. Progress towards hepatitis C virus elimination in high-income countries: An updated analysis.
    Gamkrelidze I; Pawlotsky JM; Lazarus JV; Feld JJ; Zeuzem S; Bao Y; Gabriela Pires Dos Santos A; Sanchez Gonzalez Y; Razavi H
    Liver Int; 2021 Mar; 41(3):456-463. PubMed ID: 33389788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global timing of hepatitis C virus elimination in high-income countries.
    Razavi H; Sanchez Gonzalez Y; Yuen C; Cornberg M
    Liver Int; 2020 Mar; 40(3):522-529. PubMed ID: 31815353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study.
    Chen Q; Ayer T; Bethea E; Kanwal F; Wang X; Roberts M; Zhuo Y; Fagiuoli S; Petersen J; Chhatwal J
    BMJ Open; 2019 Jun; 9(6):e026726. PubMed ID: 31189677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C.
    Sulkowski M; Cheng WH; Marx S; Sanchez Gonzalez Y; Strezewski J; Reau N
    Adv Ther; 2021 Jan; 38(1):423-440. PubMed ID: 33145648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of HCV in Russia: Barriers and Perspective.
    Isakov V; Nikityuk D
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targets.
    Petkevičienė J; Voeller A; Čiupkevičienė E; Razavi-Shearer D; Liakina V; Jančorienė L; Kazėnaitė E; Zaksas V; Urbonas G; Kupčinskas L
    BMC Public Health; 2024 Apr; 24(1):1055. PubMed ID: 38622549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
    Won YK; Kang KS; Gonzalez YS; Razavi H; Dugan E; Han KH; Ahn SH; Jeon MY; Kim DY
    PLoS One; 2020; 15(4):e0232186. PubMed ID: 32343727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries.
    Leblebicioglu H; Arends JE; Ozaras R; Corti G; Santos L; Boesecke C; Ustianowski A; Duberg AS; Ruta S; Salkic NN; Husa P; Lazarevic I; Pineda JA; Pshenichnaya NY; Tsertswadze T; Matičič M; Puca E; Abuova G; Gervain J; Bayramli R; Ahmeti S; Koulentaki M; Kilani B; Vince A; Negro F; Sunbul M; Salmon D;
    Antiviral Res; 2018 Feb; 150():9-14. PubMed ID: 29217468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis.
    Yousafzai MT; Bajis S; Alavi M; Grebely J; Dore GJ; Hajarizadeh B
    J Viral Hepat; 2021 Oct; 28(10):1340-1354. PubMed ID: 34310812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?
    Kondili LA; Blach S; Razavi H; Craxì A
    Ann Ist Super Sanita; 2020; 56(3):325-329. PubMed ID: 32959798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Family planning. A survey of United Nations around the world].
    Courr Unesco; 1974; 27():46-8. PubMed ID: 12257583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
    Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pill in figures and facts.
    Von Keep PA
    Adv Fertil Control; 1967; 2():1-5. PubMed ID: 12275322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bridging Hepatitis C Care Gaps: A Modeling Approach for Achieving the WHO's Targets in Ontario, Canada.
    Sahakyan Y; Erman A; Wong WWL; Greenaway C; Janjua N; Kwong JC; Sander B
    Viruses; 2024 Jul; 16(8):. PubMed ID: 39205198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19.
    Blach S; Blomé M; Duberg AS; Jerkeman A; Kåberg M; Klasa PE; Lagging M; Razavi-Shearer D; Razavi H; Aleman S
    Liver Int; 2021 Sep; 41(9):2024-2031. PubMed ID: 34051065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global reporting of progress towards elimination of hepatitis B and hepatitis C.
    Cui F; Blach S; Manzengo Mingiedi C; Gonzalez MA; Sabry Alaama A; Mozalevskis A; Séguy N; Rewari BB; Chan PL; Le LV; Doherty M; Luhmann N; Easterbrook P; Dirac M; de Martel C; Nayagam S; Hallett TB; Vickerman P; Razavi H; Lesi O; Low-Beer D
    Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):332-342. PubMed ID: 36764320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Let's End HepC: Modelling Public Health Epidemiological Policies Applied to Hepatitis C in Spain.
    Lopes H; Baptista-Leite R; Franco D; Serra MA; Escudero A; Martín-Moreno JM
    Front Public Health; 2021; 9():735572. PubMed ID: 35071151
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
    European Union HCV Collaborators
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCV disease burden and population segments in Switzerland.
    Bihl F; Bruggmann P; Castro Batänjer E; Dufour JF; Lavanchy D; Müllhaupt B; Negro F; Razavi H; Scheidegger C; Semela D; Semmo N; Blach S
    Liver Int; 2022 Feb; 42(2):330-339. PubMed ID: 34839578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.